BrainsWay
Update in progressBWAY (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
BrainsWay Ltd. develops and markets noninvasive neurostimulation therapies for mental health and neurology. Its Deep Transcranial Magnetic Stimulation (dTMS) platform treats major depressive disorder, anxiety, OCD, smoking, bipolar disorder, PTSD, schizophrenia, Alzheimer’s, autism, chronic pain, MS, stroke rehab, and Parkinson’s. Serving clinicians in hospitals and medical centers worldwide, BrainsWay was founded in 2003 and is headquartered in Jerusalem, Israel.
Company score
- Sentiment
- 0.55
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.54
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.19
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.37
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!